MiniMed Reports Q1 2027 Earnings: Strong Revenue Growth and Product Launches
MiniMed (MMED) reported first-quarter revenue of $843 million, reflecting a strong performance with organic growth of 15.8%. The U.S. business saw significant momentum following the launch of its MiniMed Flex insulin pump system, while international markets also contributed to robust results due to improved sensor supply and new product introductions. Key highlights include an increase in global pump sales by 7.7% year-over-year, a CGM attachment rate rising to 69%, and adjusted EBITDA of $83 million with a margin of 9.9%. The company also raised its organic revenue guidance for the year from 10% to approximately 10.5%, citing strong demand trends. MiniMed is advancing several pipeline initiatives, including FDA submissions for new products like MiniMed Fit and Vivera, which are expected to launch in late 2027 or early summer of that year.
Topics: adjusted_EBITDA CGM_attachment_rate insulin_pumps organic_growth revenue